Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by arsenic sulphide: Involvement of serine/threonine protein phosphatases

Leukemia Research

Volumn 30, Issue 11, 2006, Pages 1399-1405

  Luo, Li Yun ^a   Huang, Jian ^a   Gou, Bao Di ^a   Zhang, Tian Lan ^b   Wang, Kui ^a  

^a PEKING UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Arsenic sulfide; HL 60; Monocytic differentiation; Protein phosphatase; Realgar

Indexed keywords

ARSENIC DERIVATIVE; ARSENIC SULPHIDE; CD11B ANTIGEN; CD14 ANTIGEN; PHOSPHOPROTEIN PHOSPHATASE; SERINE THREONINE PROTEIN PHOSPHATASE 1; SERINE THREONINE PROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL STRAIN HL 60; CONTROLLED STUDY; CYTOFLUOROMETRY; DRUG MECHANISM; HUMAN; HUMAN CELL; MONOCYTE; NITROBLUE TETRAZOLIUM TEST; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ARSENICALS; CELL DIFFERENTIATION; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MONOCYTES; PHOSPHOPROTEIN PHOSPHATASE; SERINE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFIDES; THREONINE;

EID: 33748281159     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.03.016     Document Type: Article

References (45)

1. Andrew M.E., Martin S., et al. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 28 (2004) 891-900
2. Vasken H., Aposhian, Mary M., et al. Arsenic Toxicology: five questions. Chem Res Toxicol 19 (2006) 1-15
3. Rousselot P., Labaume S., Marolleau J.P., et al. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59 (1999) 1041-1048
4. Wang Z.Y. Arsenic compounds as anticancer agents. Cancer Chemother Pharm 48 (2001) 72-76
5. Yuan S.T., Zhang G.Q., Tian S.Z., et al. Research on the traditional process of preparing realgar. Zhong Yao Tong Bao 12 (1987) 23-26
6. Zhang J.X., Yuan S.T., and Zhang G.Q. History of realgar processing. Zhong Yao Tong Bao 12 (1987) 55-58
7. Gu C.H. The application of realgar in hematological diseases. Acta Universitatis Medicinalis Secondae 22 (2002) 92-94
8. Huang S.L., Guo A.X., Xiang Y., et al. Clinical study on the treatment of APL mainly with composite indigo naturalis tablets. Chin J Hematol 16 (1995) 26-28
9. Liu Y.F., Jiang B., and Lu D.P. Arsenic sulfide induces NB4 apoptosis and arrests cell growth in G2/M phase. Chin J Hematol 21 (2000) 647-648
10. 4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 104 (2004) 4219-4225
11. Tonks N.K., and Charbonneau H. Protein tyrosine dephosphorylation and signal transduction. Trends Biochem Sci 14 (1989) 497-500
12. Morita K., Nishikawa M., Kobayashi K., et al. Augmentation of retinoic acid-induced granulocytic differentiation in HL-60 leukemia cells by serine/threonine protein phosphatase inhibitors. FEBS Lett 314 (1992) 340-344
13. Collins S.J. The HL60 promyelocytic leukemia cell line: proliferation, and cellular oncogene expression. Blood 70 (1987) 1233-1244
14. Tanaka H., Abe E., Miyaura C., Shiina Y., and Suda T. 1 alpha,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. Biochem Biophys Res Commun 117 (1983) 86-92
15. Breitman T.R., Slonic S.E., and Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci 77 (1980) 2936-2940
16. Rovera G., Santoli D., and Damsky C. Human promyelocytic leukemia cells in culture differentiate into macrophage like cells when treated with a phorbol diester. Proc Natl Acad Sci 76 (1979) 2779-2783
17. Collins S.J., Gallo R.C., and Gallagher R.E. Continuous growth and differentiation of human myeloid leukemia cells in suspension culture. Nature 270 (1977) 347-349
18. Carmichael J. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47 4 (1987) 936-942
19. Kang H.K., Suh J.H., Lee J.J., et al. Induction of the differentiation of HL-60 promyelocytic leukemia cells by L-ascorbic acid. Free Radic Res 37 (2003) 1274-1291
20. Kohroki J., Muto N., Tanaka T., Itoh N., Inada A., and Tanaka K. Induction of differentiation and apoptosis by dithizone in human myeloid leukaemia cell lines. Leuk Res 22 (1998) 405-412
21. Freire A.C.G., de Assis C.F., Frick A.O., et al. Influence of protein phosphatase inhibitors on HL60 cells death induction by dehydrocrotonin. Leuk Res 27 (2003) 823-829
22. Kim T.S., Xu W.S., Sun T., and Cohen E.P. Immunization with interleukin-2/interferon-g double cytokine-secreting allogeneic fibroblasts prolongs the survival of mice with melanoma. Melanoma Res 5 (1995) 217-227
23. Kanga S.N., Lee M.H., Kim K.-M., Cho D., and Kim T.S. Induction of human promyelocytic leukemia HL-60 cell differentiation into monocytes by silibinin: involvement of protein kinase C. Biochem Pharmacol 61 (2001) 1487-1495
24. Zhu T., Matsuzawa S., Mizuno Y., et al. The interconversion of protein phosphatase 2A between PP2A1 and PP2A0 during retinoic acid-induced granulocytic differentiation and a modification on the catalytic subunit in S phase of HL-60 cells. Arch Biochem Biophys 339 (1997) 210-217
25. Yasuda I., Kishimoto A., Tanaka S., Tominaga M., Sakurai A., and Nishizuka Y. A synthetic peptide substrate for selective assay of protein kinase C. Biochem Biophys Res Commun 166 (1990) 1220-1227
26. Kansas G.S., Muirhead M.J., and Dailey M.O. Expression of the CD11/CD18, leukocyte adhesion molecule 1, and CD44 adhesion molecules during normal myeloid and erythroid differentiation in humans. Blood 76 (1990) 2483-2492
27. Wright S.D., Ramos R.A., Tobias P.S., Ulevitch R.J., and Mathison J.C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 249 (1990) 1431-1433
28. Vahter M. Mechanisms of arsenic biotransformation. Toxicology 181/182 (2002) 211-217
29. Unnikrishnan D., Dutcher D., Varshneya J.P., et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood 97 (2001) 1514-1516
30. Westervelt P., Brown R.A., Adkins D.R., et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98 (2001) 266-271
31. Kwong Y.L., and Todd D. Delicious poison: arsenic trioxide for the treatment of leukemia. Blood 89 (1997) 3487-3488
32. Chen Z., Chen G.Q., Shen Z.X., et al. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol 38 (2001) 26-36
33. Jia Y.-m., and Liu S.-x. Clinical investigation of realgar to acute promyelocytic leukemia. Chin J Prim Med Pharm 11 (2004) 138-139
34. Lu D.P., Qiu J.Y., Jiang B., et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99 (2002) 3136-3143
35. Wang F.R., Luo Y.Q., and Lu D.P. A clinical pharmacokinetic study of multi-dose oral tetra-arsenic tetra-sulfide combination therapy in acute promyelocytic leukemia. Zhonghua Nei Ke Za Zhi 44 (2005) 730-733
36. 3, all trans-retinoic acid, rTGF-b2 and their combinations. J Steroid Biochem 60 (1997) 87-97
37. Collins S.J., Ruscetti F.W., Gallagher R.E., and Gallo R.C. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci 75 (1978) 2458-2462
38. Breitman T.R., Selonick S.E., and Collins S.J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci 77 (1980) 2936-2940
39. Fischkoff S.A., Pollak A., Gleich G.J., Testa J.R., Misawa S., and Reber T.J. Eosinophilic differentiation of the human promyelocytic leukemia cell line, HL-60. J Exp Med 160 1 (1984) 179-196
40. Hutt-Taylor S.R., Harnish D., Richardson M., Ishizaka T., and Denburg J.A. Sodium butyrate and a T lymphocyte cell line-derived differentiation factor induce basophilic differentiation of the human promyelocytic leukemia cell line HL-60. Blood 71 1 (1988) 209-215
41. Ujihara M., Nomura K., Yamada O., and Deura H. Establishment of a stable HL60 subline having the potential for monocytic differentiation using granulocyte-macrophage colony-stimulating factor: possible use for the study of monocytic differentiation and oxidative stress. Atherosclerosis 139 (1998) 301-306
42. Drayson M.T., Michell R.H., Jennifer D., and Geoffrey B. Cell proliferation and CD11b expression are controlled independently during HL60 cell differentiation initiated by 1,25α-dihydroxyvitamin D3 or all-trans-retinoic acid. Exp Cell Res 266 (2001) 126-134
43. Yuksel S., Saydam G., Uslu R., et al. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res 26 (2002) 391-398
44. Zhu Q., Zhang J.-W., Zhu H.-Q., et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99 (2002) 1014-1022
45. Aydin H.H., Selvi N., Saydam G., et al. Up-regulation of serine/threonine phosphatase type 2A regulatory subunits during methylprednisolone-induced differentiation of leukemia HL60 cells. Clin Lab Haematol 22 (2000) 271-274